LOTENSIN HCT Drug Patent Profile

Which patents cover Lotensin Hct, and what generic alternatives are available?

Lotensin Hct is a drug marketed by Validus Pharms and is included in one NDA.

The generic ingredient in LOTENSIN HCT is benazepril hydrochloride; hydrochlorothiazide. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the benazepril hydrochloride; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lotensin Hct

A generic version of LOTENSIN HCT was approved as benazepril hydrochloride; hydrochlorothiazide by ANI PHARMS on February 11^th, 2004.

Summary for LOTENSIN HCT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	13
Patent Applications:	3,249
Drug Prices:	Drug price information for LOTENSIN HCT
What excipients (inactive ingredients) are in LOTENSIN HCT?	LOTENSIN HCT excipients list
DailyMed Link:	LOTENSIN HCT at DailyMed

See drug prices for LOTENSIN HCT

Recent Clinical Trials for LOTENSIN HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanjing Children's Hospital	Phase 2
University of Nebraska	Phase 4
Peking University First Hospital	Phase 1/Phase 2

See all LOTENSIN HCT clinical trials

Pharmacology for LOTENSIN HCT

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Decreased Blood Pressure Increased Diuresis

US Patents and Regulatory Information for LOTENSIN HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-001	May 19, 1992		DISCN	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-003	May 19, 1992	AB	RX	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-002	May 19, 1992	AB	RX	Yes	No
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-004	May 19, 1992	AB	RX	Yes	No

Expired US Patents for LOTENSIN HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-001	May 19, 1992	4,410,520*PED
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-002	May 19, 1992	4,410,520*PED
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-003	May 19, 1992	4,410,520*PED
Validus Pharms	LOTENSIN HCT	benazepril hydrochloride; hydrochlorothiazide	TABLET;ORAL	020033-004	May 19, 1992	4,410,520*PED

International Patents for LOTENSIN HCT

See the table below for patents covering LOTENSIN HCT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0119955	3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE
Australia	8701482
Spain	544255
Ireland	840302
Japan	H057384
Spain	514856
Hungary	192394	PROCESS FOR PREPARING DERIVATIVES OF 3-/5-AMINO-PENTYL/-AMINO-1-BENZAZEPIN-2-ONE-1-ALKANE-CARBOXYLIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS

Market Dynamics and Financial Trajectory for LOTENSIN HCT

Last updated: February 20, 2026

What is LOTENSIN HCT?

LOTENSIN HCT combines telmisartan and hydrochlorothiazide. It is approved for treating hypertension by reducing blood pressure. The drug market is influenced by its positioning as a combination therapy targeting resistant hypertension and patients needing fixed-dose combinations.

Market Size and Growth Estimates

The global antihypertensive drugs market was valued at approximately USD 36.6 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% from 2023 to 2030, reaching USD 50.7 billion by 2030 [1].

The segment for combination therapies, including drugs like LOTENSIN HCT, accounts for roughly 35-40% of this market. The preference for once-daily, fixed-dose combination drugs drives growth.

Market Drivers

1. Increasing Hypertension Prevalence: Current estimates report approximately 1.39 billion adults globally with hypertension, increasing demand for effective treatments [2].

2. Patient Preference for Combination Therapy: Fixed-dose combinations improve compliance, reduce pill burden, and lead to better blood pressure control.

3. Expanding Cardiovascular Disease (CVD) Management Markets: Rising awareness and screening programs for CVD foster higher drug utilization.

4. Patent Status and Market Exclusivity: Telmisartan's patent expired in various jurisdictions post-2017, opening competition but maintaining interest through branded formulations like LOTENSIN HCT.

Competitive Landscape

• Key Competitors: Co-packaged fixed-dose combinations of telmisartan and hydrochlorothiazide by multiple generic manufacturers.
• Market Penetration: ROUND 1, branded versions like LOTENSIN HCT have maintained significant share, especially in markets with high brand loyalty.
• Pricing Strategies: Generics drive prices downward, but branded formulations persist with premium pricing by leveraging physician preferences.

Regulatory and Reimbursement Environment

• Market Access: Reimbursement policies favor generic substitution; however, branded drugs like LOTENSIN HCT retain premium positioning in certain markets due to physician preference.
• Approval Timelines: In major markets like the US, Europe, and Japan, regulatory approvals date back to the late 2000s to early 2010s, with post-approval updates on indications.

Financial Trajectory

Revenue Estimation

• The drug generates estimated annual sales of USD 150-200 million globally, with the majority from North America and Europe.
• US sales account for approximately 60% of revenue; the rest derived mainly from Europe, Asia, and select emerging markets.

Sales Trends

• Sales have shown steady growth in the last five years, driven by increased awareness, prescription rates, and expanded market access.
• Price erosion has occurred especially in mature markets due to competition from generics.

Future Revenue Opportunities

• Market Expansion: Entering emerging markets with high hypertension prevalence may add USD 50-100 million in annual revenue over the next five years.
• Line Extensions: Developing new fixed-dose combinations or indications might create incremental revenue streams.

Risks

• Patent expiring in key regions, leading to increased generic competition.
• Prescribing trends shifting toward newer therapies or alternative drug classes.
• Pricing pressures from payers and regulatory agencies.

Market Outlook

The outlook for LOTENSIN HCT remains cautiously optimistic. Although generic competition limits premium pricing, steady demand for antihypertensive combination agents sustains revenues. Expansion into emerging markets and formulation innovations can offset some revenue decline from patent expirations.

---

Key Takeaways

• The global antihypertensive market expands at a CAGR of 3.9%, with fixed-dose combinations contributing significantly.
• Revenue for LOTENSIN HCT is estimated at USD 150-200 million annually, primarily in mature markets.
• Patent expirations have introduced price competition, but brand loyalty sustains sales.
• Market growth depends on expanding into emerging markets and introducing new formulations.
• Pricing pressures and generics dominate future revenue prospects.

---

FAQs

Q1: How long will LOTENSIN HCT maintain exclusivity in key markets?
Patent protection for telmisartan in the US expired in 2017; the combination formulation’s patent status varies by jurisdiction, often expiring between 2018 and 2023. Post-patent, generic competition accelerates.

Q2: What are the primary factors influencing sales decline?
Patent expirations, increased generic competition, pricing erosion, and shifting prescribing patterns towards newer antihypertensives.

Q3: Is there potential for growth through new indications?
Limited; LOTENSIN HCT is solely indicated for hypertension. Development of new fixed-dose combinations or combination therapies could create incremental revenue.

Q4: How does reimbursement impact market penetration?
Reimbursement policies favor generics, creating downward pressure on prices. Branded drugs maintain premiums where physicians prefer them or where brand loyalty exists.

Q5: What is the outlook for emerging markets?
Growing hypertension prevalence and improving healthcare infrastructure suggest significant growth opportunities, potentially adding USD 50-100 million annually over five years.

---

References

[1] Market Research Future. (2022). Antihypertensive Drugs Market Report.
[2] World Health Organization. (2021). Hypertension Fact Sheet.